Vor Biopharma Inc.
VOR
$16.10
$1.177.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -644.61% | -495.29% | -2,078.10% | -1,309.41% | 1.36% |
| Total Depreciation and Amortization | -38.71% | -18.17% | 4.89% | 27.27% | -5.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5,360.57% | 3,836.83% | 17,701.81% | 12,248.14% | 3.85% |
| Change in Net Operating Assets | -281.17% | 204,060.00% | 374.76% | 311.79% | 153.24% |
| Cash from Operations | -49.50% | -43.20% | -44.52% | -8.98% | 5.85% |
| Capital Expenditure | -119.08% | -310.92% | -160.82% | 30.04% | 68.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -688.40% | -150.12% | -100.00% | -100.00% | -51.63% |
| Cash from Investing | -692.18% | -150.39% | -99.91% | -99.79% | -51.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 940.64% | 801.67% | 16,994.08% | 7,436.98% | 3,658.22% |
| Repurchase of Common Stock | 2.43% | 23.72% | 58.15% | 60.63% | 78.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 68.67% | 43.01% | -- | -- | -- |
| Cash from Financing | 999.42% | 843.60% | 190,200.76% | 85,533.83% | 10,131.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,213.22% | 517.31% | 1,256.39% | 161.03% | 102.59% |